Clinical Trial Update: GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

GT719 Injection is being studied in a Phase 1/2 trial for recurrent or refractory CD19-positive adult B-cell malignancies, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• GT719 Injection (GT719)

Snippet

Sponsor: Grit Biotechnology | Conditions: Hematological Malignancy (Leukemia- Lymphoma) | Phase 1, Phase 2 | Status: RECRUITING